Partners

BioInvent is pioneering the field of immuno-oncology and conducts research cooperation with leading academic research institutions including:

Mark Cragg, Professor of Experimental Cancer Research and director of the Cancer Pathway Integrated Postgraduate Program at the University of Southampton, is a leading researcher in antibody biology.

Cancer Research Technology (CRT), a specialist commercialisation and development company, which aims to develop new discoveries in cancer research for the benefit of cancer patients. CRT is a wholly owned subsidiary of Cancer Research UK, the world's leading cancer charity dedicated to saving lives through research. Further information about CRT can be found atwww.cancertechnology.com

In December 2016, BioInvent signed a strategic research collaboration with Pfizer Inc to develop antibodies targeting tumour-associated myeloid cells.

University of Southampton

Cancer Research UK

Technology partnerships

The Company has also several licensing agreements and, in some cases, research collaborations with a number of external partners including Bayer Pharma, Daiichi Sankyo, Mitsubishi Tanabe Pharma and Xoma. The structure and terms of these agreements and partnerships vary, but they all have in common that BioInvent receives license fees, research financing, milestone payments and royalties on the sale of commercial products. Of these external drug development programmes, one project is currently in Phase II, three in Phase I and one is in the preclinical phase.